Stockreport

Heat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial at the Genitourinary Cancers Symposium

Heat Biologics, Inc.  (HTBX) 
Last heat biologics, inc. earnings: 8/14 07:00 am Check Earnings Report
PDF DURHAM, N.C., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), announced that it presented a poster of its immunological data from its 94 [Read more]